Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | CTSG | P08311 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | CTRC | Q99895 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740424 | 0.86 | KDM4E (0.59) | ADORA2AALDH1A1HPGDMT-CO2ALOX5 | |
| SCHEMBL11056954 | 0.81 | KMT2A (0.58) | ADORA2AALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL5738724 | 0.81 | KDM4E (0.60) | ADORA2AALDH1A1HPGDMT-CO2ALOX5 | |
| SCHEMBL14254741 | 0.78 | SMN1; SMN2 (0.47) | ADORA2AALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17926108 | 0.77 | ADORA2A (0.54) | ADORA2AALDH1A1HPGDEP300MEN1 | |
| SCHEMBL4555734 | 0.77 | THRB (0.60) | HTR1A | |
| SCHEMBL1449456 | 0.77 | ALDH1A1 (0.66) | ADORA2AALDH1A1HPGDMT-CO2ALOX5 | |
| SCHEMBL13879471 | 0.75 | ADORA2A (1.00) | ADORA2AALDH1A1EP300KMT2A | |
| SCHEMBL11065237 | 0.75 | MEN1 (0.81) | ADORA2AALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL1021890 | 0.74 | ALDH1A1 (0.61) | ADORA2AALDH1A1HPGDMT-CO2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114085219-B | Synthesis of (1S, 6R) -8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3.0] nonane | 武汉理工大学 | 2023-08-01 | — | — | CN | claimed |
| CN-114085219-A | Synthesis of (1S,6R) -8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3.0] nonane | 武汉理工大学 | 2022-02-25 | — | — | CN | claimed |
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | claimed |
| EP-1244670-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL Holdings, Inc. (US) | 2002-10-02 | — | — | EP | claimed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | claimed |
| WO-2001046195-A1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | GPI NIL HOLDINGS, INC. (US) | 2001-06-28 | — | — | WO | claimed |
| CN-114085219-B | Synthesis of (1S, 6R) -8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3.0] nonane | 武汉理工大学 | 2023-08-01 | — | — | CN | disclosed |
| CN-114085219-A | Synthesis of (1S,6R) -8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3.0] nonane | 武汉理工大学 | 2022-02-25 | — | — | CN | disclosed |
| CN-114085219-A | Synthesis of (1S,6R) -8-benzyl-7, 9-dioxo-2, 8-diazabicyclo [4.3.0] nonane | 武汉理工大学 | 2022-02-25 | — | — | CN | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-1244670-B1 | HYDANTOIN DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USING SAME | MGI GP INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6974823-B2 | Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same | GPI NIL HOLDINDGS, INC. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-10-30 | — | — | US | disclosed |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | GLIAMED, INC. | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203890-A1 | Method for treating nerve injury caused as a result of surgery | NGF, BDNF, GAP43 | ADORA2A 1771/4885ALDH1A1 824/4885HPGD 424/4885 |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | ADORA2A 4445/4885ALDH1A1 1500/4885HPGD 2354/4885 |
| US-20020058685-A1 | Hydantoin derivative compounds, pharmace utical compositions, and methods of using same | HNMT, HAAO, HTR3E | ADORA2A 1504/4885ALDH1A1 1066/4885HPGD 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.